# Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

> **NCT03072160** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 17 (actual)

## Conditions studied

- Medullary Thyroid Cancer (MTC)

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03072160
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-16
- **Primary completion:** 2019-11-22
- **Final completion:** 2019-11-22
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2021-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03072160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03072160, "Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer". Retrieved via MORVS 2026-10-31 from https://api.morvs.ai/clinical/NCT03072160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*